Jason Hoitt
Corporate Officer/Principal at STOKE THERAPEUTICS, INC.
Jason Hoitt active positions
| Companies | Position | Start | End |
|---|---|---|---|
| STOKE THERAPEUTICS, INC. | Corporate Officer/Principal | 14/04/2024 | - |
Career history of Jason Hoitt
Former positions of Jason Hoitt
| Companies | Position | Start | End |
|---|---|---|---|
| PROVENTION BIO, INC. | Corporate Officer/Principal | 31/05/2020 | 31/05/2023 |
| DOVA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 15/12/2018 | 11/11/2019 |
| INSMED INCORPORATED | Sales & Marketing | 30/04/2017 | - |
| SAREPTA THERAPEUTICS, INC. | Sales & Marketing | 31/12/2012 | 30/04/2017 |
Training of Jason Hoitt
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Statistics
International
| United States | 7 |
Operational
| Corporate Officer/Principal | 3 |
| Sales & Marketing | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| INSMED INCORPORATED | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| STOKE THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
- Stock Market
- Insiders
- Jason Hoitt
- Experience